Production and quality control of medicinal products derived by recombinant DNA technology - Scientific guideline
HumanScientific guidelines
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
This document provides quality recommendation for medicinal products derived by recombinant DNA technology. It aims to facilitate the application of Part 2, section A-E of the annex to Directive 75/318/EC. It has been superseded by ICH Q5B, ICH Q5D and ICH Q6B.
Keywords: Recominant, DNA, rDNA, quality control,fermentation, purification, cell banking characterisation, biological potency, purity, specifications